75,500 Shares in Dova Pharmaceuticals Inc (NASDAQ:DOVA) Purchased by Gabelli Funds LLC

Gabelli Funds LLC bought a new position in shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 75,500 shares of the company’s stock, valued at approximately $2,110,000. Gabelli Funds LLC owned 0.26% of Dova Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. grew its holdings in Dova Pharmaceuticals by 231.5% during the third quarter. Meeder Asset Management Inc. now owns 988 shares of the company’s stock worth $27,000 after acquiring an additional 690 shares during the period. Capital Investment Advisory Services LLC grew its holdings in Dova Pharmaceuticals by 222.2% during the second quarter. Capital Investment Advisory Services LLC now owns 2,900 shares of the company’s stock worth $45,000 after acquiring an additional 2,000 shares during the period. Quantamental Technologies LLC grew its holdings in Dova Pharmaceuticals by 1,100.0% during the second quarter. Quantamental Technologies LLC now owns 2,400 shares of the company’s stock worth $34,000 after acquiring an additional 2,200 shares during the period. Doyle Wealth Management acquired a new position in Dova Pharmaceuticals during the second quarter worth about $49,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Dova Pharmaceuticals by 6.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 67,386 shares of the company’s stock worth $951,000 after acquiring an additional 3,992 shares during the period. 32.22% of the stock is currently owned by hedge funds and other institutional investors.

DOVA traded up $0.02 during trading on Friday, reaching $28.00. The company had a trading volume of 1,865,500 shares, compared to its average volume of 351,851. The firm’s 50-day simple moving average is $26.21 and its 200 day simple moving average is $16.27. Dova Pharmaceuticals Inc has a 12-month low of $5.62 and a 12-month high of $28.54. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.37 and a current ratio of 5.64. The company has a market cap of $806.74 million, a price-to-earnings ratio of -10.77 and a beta of 2.74.

A number of equities analysts recently weighed in on DOVA shares. JPMorgan Chase & Co. raised Dova Pharmaceuticals from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $16.00 to $28.00 in a research note on Thursday, October 3rd. HC Wainwright cut Dova Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $45.00 to $27.50 in a research note on Monday, September 30th. ValuEngine cut Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. BidaskClub cut Dova Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Finally, Oppenheimer started coverage on Dova Pharmaceuticals in a research note on Thursday, August 29th. They issued an “outperform” rating and a $30.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $26.42.

In other Dova Pharmaceuticals news, insider Jason Hoitt sold 2,387 shares of Dova Pharmaceuticals stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $28.00, for a total value of $66,836.00. Also, CEO David Zaccardelli sold 5,275 shares of Dova Pharmaceuticals stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $27.90, for a total value of $147,172.50. Over the last 90 days, insiders sold 14,458 shares of company stock valued at $379,497. Corporate insiders own 60.30% of the company’s stock.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

See Also: Overbought

Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).

Institutional Ownership by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply